We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

184 hedge funds and large institutions have $761M invested in Acorda Therapeutics in 2019 Q1 according to their latest regulatory filings, with 26 funds opening new positions, 79 increasing their positions, 41 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

93% more repeat investments, than reductions

Existing positions increased: 79 | Existing positions reduced: 41

24% more first-time investments, than exits

New positions opened: 26 | Existing positions closed: 21

3% more funds holding

Funds holding: 179 → 184 (+5)

8% less capital invested

Capital invested by funds: $826M → $761M (-$65M)

52% less call options, than puts

Call options by funds: $2.4M | Put options by funds: $5.05M

Holders
184
Holders Change
+5
Holders Change %
+2.79%
% of All Funds
3.98%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
26
Increased
79
Reduced
41
Closed
21
Calls
$2.4M
Puts
$5.05M
Net Calls
-$2.65M
Net Calls Change
-$26M

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$27.4M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$11.5M
3
State Street
State Street
Massachusetts
+$9.6M
4
Prudential Financial
Prudential Financial
New Jersey
+$6.06M
5
Acadian Asset Management
Acadian Asset Management
Massachusetts
+$5.08M

Top Sellers

Rank Fund Capital Flow
1
PHS
PFM Health Sciences
California
-$17.3M
2
Invesco
Invesco
Georgia
-$17.1M
3
SCM
Scopia Capital Management
New York
-$15.5M
4
Millennium Management
Millennium Management
New York
-$11M
5
Balyasny Asset Management
Balyasny Asset Management
Illinois
-$4.28M
Name Holding Trade Value Shares
Change 		Change in
Stake
Charles Schwab
26
Charles Schwab
California
$4.26M +$21.6K +12 +0.5%
Ameriprise
27
Ameriprise
Minnesota
$4.05M +$186K +103 +4%
BBA
28
Baker Bros. Advisors
New York
$3.88M +$4.38M +2,434 New
AQR Capital Management
29
AQR Capital Management
Connecticut
$3.73M +$1.71M +951 +69%
Diamond Hill Capital Management
30
Diamond Hill Capital Management
Ohio
$3.66M +$3.66M +2,032 +779%
Schroder Investment Management Group
31
Schroder Investment Management Group
United Kingdom
$3.61M -$171K -95 -4%
Two Sigma Advisers
32
Two Sigma Advisers
New York
$3.57M +$1.58M +876 +64%
OM
33
Opaleye Management
Massachusetts
$3.52M +$3.98M +2,208 New
Connor, Clark & Lunn Investment Management (CC&L)
34
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
$3.37M +$542K +301 +17%
JP Morgan Chase
35
JP Morgan Chase
New York
$3.23M -$59.5K -33 -2%
Point72 Asset Management
36
Point72 Asset Management
Connecticut
$3.22M +$3.64M +2,018 New
PAMU
37
Pictet Asset Management (UK)
United Kingdom
$3.19M +$1.21M +673 +51%
Wellington Management Group
38
Wellington Management Group
Massachusetts
$2.95M – – –
BCM
39
Bridgeway Capital Management
Texas
$2.88M – – –
Bank of America
40
Bank of America
North Carolina
$2.83M -$175K -97 -5%
Squarepoint
41
Squarepoint
New York
$2.81M +$1.51M +837 +90%
Russell Investments Group
42
Russell Investments Group
United Kingdom
$2.69M +$1.47M +815 +93%
TCIM
43
TIAA CREF Investment Management
New York
$2.69M -$77.5K -43 -2%
Federated Hermes
44
Federated Hermes
Pennsylvania
$2.6M +$2.49M +1,381 +548%
American Century Companies
45
American Century Companies
Missouri
$2.55M +$422K +234 +17%
Teacher Retirement System of Texas
46
Teacher Retirement System of Texas
Texas
$2.46M +$2.78M +1,543 New
D.E. Shaw & Co
47
D.E. Shaw & Co
New York
$2.42M -$1.02M -565 -27%
TA
48
Teachers Advisors
New York
$2.19M +$113K +63 +5%
Robeco Institutional Asset Management
49
Robeco Institutional Asset Management
Netherlands
$2.13M +$683K +379 +40%
NC
50
Nexthera Capital
New York
$2.06M +$2.32M +1,290 New
1
2
3 4 5

ACOR Hedge Fund Activity: Q1 2019 in Review

184 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q1 2019, worth a combined $761M — down 7.9% from $826M a quarter earlier.

Buyers outnumbered sellers: 26 funds opened new ACOR positions and 21 closed out — a net gain of 5 holders — while 79 added to existing stakes and 41 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $27.4M. The largest seller was PFM Health Sciences, exiting entirely with an estimated $17.3M sold.

  • 184 institutional investors held Acorda Therapeutics (ACOR) as of Q1 2019, up from 179 in Q4 2018.
  • Funds reported $761M of Acorda Therapeutics stock for Q1 2019, down 7.9% quarter-over-quarter.
  • 26 funds opened new Acorda Therapeutics positions in Q1 2019 and 21 closed out, a net change of +5 holders.
  • The largest Acorda Therapeutics buyer in Q1 2019 was Renaissance Technologies, an estimated $27.4M added.
  • The largest Acorda Therapeutics seller in Q1 2019 was PFM Health Sciences, an estimated $17.3M sold.

Based on aggregated 13F filings for Q1 2019.